TAS-103 dihydrochloride (BMS-247615 dihydrochloride)
(Synonyms: 6-[[2-(二甲基氨基)乙基]氨基]-3-羟基-7H-茚并[2,1-C]喹啉-7-酮二盐酸盐,BMS-247615 dihydrochloride) 目录号 : GC32822A DNA topoisomerase I and II inhibitor
Cas No.:174634-09-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
TAS 103 is an inhibitor of DNA topoisomerase I and II (IC50s = 2 and 6.5 ?M, respectively).1 It stabilizes topoisomerase I-DNA and topoisomerase II-DNA cleavable complexes in KB cells when used at a concentration of 3 ?M. It is cytotoxic to P388 and KB cells (IC50s = 1.1 and 9.6 nM, respectively). TAS 103 (15, 26, and 45 mg/kg per day) reduces pulmonary metastasis in murine B16-BL6 melanoma and UV-2237M fibrosarcoma models of lung metastasis. It also reduces tumor growth in a variety of human cancer mouse xenograft models.
1.Utsugi, T., Aoyagi, K., Asao, T., et al.Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and IIJpn. J. Cancer Res.88(10)992-1002(1997)
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.4612 mL | 12.3059 mL | 24.6117 mL |
5 mM | 0.4922 mL | 2.4612 mL | 4.9223 mL |
10 mM | 0.2461 mL | 1.2306 mL | 2.4612 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。